Clinical Trials Logo
  1. Home
  2. Drug-drug Interaction
  3. NCT04542252

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction Clinical Trial

Official title:
An Open-label, Randomized, Crossover Study to Evaluate the Drug Interaction of Coadministered Cyclosporine on the Pharmacokinetics and Safety of Intravenous Administration of SyB V-1901 in Japanese Healthy Subjects

Clinical Trial Summary

To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion in healthy adult subjects

Clinical Trial Description

This study is an open-label, randomized and crossover study designed to evaluate the effect of cyclosporine on the pharmacokinetics of SyB V-1901. Healthy adult subjects will receive an IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and coadministration of cyclosporine at 2 hours after completion of SyB V-1901 infusion. Eligible subjects will be randomized to one of two groups, to receive the treatment sequence of assigned group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04542252
Study type Interventional
Source SymBio Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date November 9, 2020
Completion date January 29, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1